VIKTORIA-2 Trial Evolves to Evaluate Gedatolisib in Endocrine-Sensitive and -Resistant Breast Cancer
Significant protocol amendments have been made to the ongoing phase 3 VIKTORIA-2 clinical trial (NCT06757634).The study, ...
CAR T therapy spreads beyond academic centers, but insurance, cost and policy gaps keep most eligible lymphoma patients from ...
FDA fast track status was supported by two monotherapy responses in MSI-H colorectal cancer, including one complete response ...
Six-month durability of response reached 94.5% (95% CI, 86.1%-97.9%) among 3-month complete responders, supporting clinically meaningful durability in recurrent LG-IR ...
A new program for young cancer patients breaks disease silos, showing how multidisciplinary teamwork improves coordination, ...
Dr. Doroshow addresses financial toxicity as a central concern in Sandra's case and broader challenge in HER2-directed ...
Complete response at 3 months was 79.6% (191/240), with duration-of-response estimates showing a gradual attrition over time ...
VOLGA randomizes cisplatin-ineligible MIBC patients to radical cystectomy-based standard care versus perioperative immunotherapy–ADC regimens, using dual primary endpoints of EFS and OS. Perioperative ...
In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant. Orca-T, an investigational allogeneic T-cell ...
During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.
Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...
Accelerated approval targets R/R MCL after prior BTK inhibition, addressing an area of high unmet need with limited established salvage standards. Phase 1/2 data at 320 mg QD showed ORR 52.4% and CR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results